摘要
目的研究非甾体类抗炎药塞来昔布对肺癌细胞血管生成的抑制作用。方法选用肺癌A549细胞系体外培养,在不同塞来昔布浓度作用下,应用MTT法检测肺癌细胞的增殖抑制,RT-PCR法观察肺癌细胞血管内皮生长因子mRNA(VEGFmRNA)的表达水平;裸鼠移植瘤实验检测塞来昔布在体内对肺癌细胞的抑制作用,并用免疫组化法检测移植瘤微血管密度。结果塞来昔布对肺癌细胞增殖有抑制作用,且呈剂量依赖关系,IC50为50μmol/L;RT-PCR法中,对照组肺癌细胞VEGFmRNA的表达水平高于药物组(P<0.05),药物组中肺癌细胞VEGFmRNA表达水平与塞来昔布浓度相关;裸鼠移植瘤实验中,对照组瘤重平均(2.1567±0.9750)g,药物组平均(0.9783±0.5423)g,两组有显著性差异(P<0.05),抑瘤率为54.64%;移植瘤微血管密度药物组低于对照组(P<0.05)。结论塞来昔布在体内及体外均对肺癌细胞表现出抑制作用,其作用与抑制肺癌细胞血管生成相关。
Objective To investigate the inhibitory effect of celecoxib on angiogenesis in lung cancer.Methods Different doses of celecoxib were added to the lung cancer cell line of A549 to demonstrate its biological function. MTT was performed to reveal the inhibitory effect on cell proliferation,and VEGF mRNA level in A549 was measured by RT-PCR. For in vivo study, nude mice model for tumor transplantation was developed to observe the inhibitory role of celecoxib on tumor proliferation;tumor microvessel density (MVD) was monitored by immnohistochemistry.Results There was a dose-dependent inhibition of cell proliferation by celecoxib. IC50 was 50 μmol/L.A higher level of VEGF mRNA was observed in test group than that in control group (P<0.05).In addition, the expression level of VEGF mRNA correlated with the concentration of celecoxib.The average weight of tumor nodules in control group was (2.1567±0.9750) g, while that in the experimental group was (0.9783±0.5423) g,the inhibitive rate being 54.64%,with statistically significant difference(P<0.05). The MVD of transplanted tumor in test group manifested a significant decrease,compared with control group (P<0.05).Conclusion Celecoxib inhibits the proliferation of lung cancer cell in vitro and in vivo, which may account for its inhibitory effect on angiogenesis.
出处
《武警医学》
CAS
2004年第9期650-653,共4页
Medical Journal of the Chinese People's Armed Police Force
